Benlysta is an innovative lupus treatment that is delivered via IV. This treatment first earned the green light from the U.S. Food and Drug Administration (FDA) in 2011.   Benlysta contains an active ingredient known as belimumab, which is a monoclonal antibody. Monoclonal antibodies are specialized proteins crafted in the laboratory. Benlysta is developed to act as a targeted agent, seeking out and attaching itself to certain substances in the body. This approach allows for a precise and tailored response to the challenges presented by lupus. However, this treatment is not intended for those who have severe, active central nervous system lupus.   Benlysta's impact extends beyond symptom management and aims to improve the overall quality of life for people living with lupus. Many patients describe this treatment as a turning point, as it can offer significant relief from symptoms that have been challenging to manage through other methods. If you have lupus and are looking for a way to enhance your wellness, it’s advised that you consult one of our experts about this treatment.